Shaping national networks to improve patient access to advanced therapy medicinal products in Europe
Advanced therapy medicinal products (ATMPs) offer the potential to address unmet medical needs, yet ensuring sustainable patient access remains challenging. In response, national ATMP networks are being established across Europe to strengthen ATMP development, cooperation between stakeholders and patient access. This targeted review provides an overview of (emerging) national ATMP networks across Europe and reflects on learnings and best practices. Drawing on insights from a Dutch multistakeholder workshop, a targeted European survey and interviews with established networks in the UK, Sweden and Ireland, this review concludes with recommendations to support the establishment of ATMP networks and improve patient access to ATMPs.
Authors
- Daniël O. Warmerdam (ORCID: https://orcid.org/0000-0003-1606-7448)
- Lourens T. Bloem (ORCID: https://orcid.org/0000-0002-0014-8625)
- Juan Francisco Hernandez
- Mike Broeders (ORCID: https://orcid.org/0000-0003-0462-5844)
- Pauline Meij (ORCID: https://orcid.org/0000-0003-3370-9932)
- Joyce M. Hoek (ORCID: https://orcid.org/0000-0003-3003-3199)
- Heather Main
- Renske M.T. ten Ham
Institutions
- Utrecht University (NL)
- Leiden University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Emma Kinderziekenhuis (NL)
- AstraZeneca (Netherlands) (NL)
- Pharmo Institute (NL)
- Institute for Sustainable Development (ET)
- Hoya (Japan) (JP)
Publication Details
- Journal
- Drug Discovery Today
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1016/j.drudis.2026.104661
- Primary Topic
- Biomedical Ethics and Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00